RetiredUnitedHealthcarePolicy CS029LA.R

Cytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Louisiana Only)

Policy governing the use of ductal lavage, nipple aspirate fluid collection, and fiberoptic ductoscopy for breast cancer screening or diagnosis in Louisiana; identifies these services as unproven and not medically necessary for screening or diagnostic purposes.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Louisiana Only)

Policy CodePolicy CS029LA.R

Change TypeRetirement / Revision (effective 11/01/2025retired 04/01/2026)

Effective DateNovember 1, 2025 - March 31, 2026

Next Review DateN/A

Key ActionDo not submit claims for ductal lavage, nipple aspirate cytology, or fiberoptic ductoscopy for breast cancer screening or diagnosis; these services are considered not medically necessary and may be denied.

SourceLink

POLICY UPDATE CHANGES

Policy retired effective April 1, 2026.

Retired policy; Louisiana plan membership disenrolled on Apr. 1, 2026.

Updated Supporting Information, Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information (11/01/2025).

3unproven procedures

19499example code

NCCN 2025guideline cited

38.9%

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

94%pooled sensitivity

Coverage Criteria

Not Medically Necessary

Services considered unproven and not medically necessary for screening, diagnosis, or as alternatives to guide surgery:

Primary NMN statement: Breast ductal lavage; Breast ductal fluid aspiration and cytology; Fiberoptic ductoscopy, with or without ductal lavage

Insufficient evidence of efficacy for breast cancer screening or diagnosis or to guide surgery.

The following procedures are considered unproven and not medically necessary for breast cancer screening, breast cancer diagnosis, or as alternative tools to guide surgery: breast ductal lavage; breast ductal fluid aspiration and cytology; and fiberoptic ductoscopy, with or without ductal lavage. The policy provides these determinations based on insufficient evidence of efficacy and does not list specific clinical exceptions for these indications in this portion of the document.

Published evidence on fiberoptic ductoscopy (FDS) is principally preliminary and cross‑sectional, focused on technical success, diagnostic accuracy, or feasibility. FDS is technically challenging, uncomfortable for some patients, examines only a limited portion of the ductal system, and often cannot reach peripheral lesions. There is no high‑quality evidence that ductoscopy improves breast cancer detection rates, leads to earlier‑stage diagnosis, or reduces breast cancer mortality; further studies are needed to substantiate any outcome benefit.

Ductal lavage, nipple smear/aspirate cytology (NAF), and other ductal fluid cytologic examinations are considered not medically necessary for breast cancer screening or routine diagnosis. Evidence shows limitations in diagnostic accuracy, high rates of inadequate samples, and no demonstrated improvement in patient outcomes. Notably, NCCN (2025) does not recommend ductal lavage and does not routinely recommend nipple smear cytology for patients with nipple discharge without palpable symptoms.

Available data do not demonstrate that fiberoptic ductoscopy or related intraductal procedures produce meaningful clinical outcome benefits. In particular, studies have not shown that ductoscopy or associated ductal fluid cytology lead to earlier‑stage diagnosis or reduced breast cancer mortality, and current evidence is insufficient to support their use to improve clinical outcomes.

Coding

Applicable/Reference CPT codesCPT

19499

Unlisted procedure, breast

Provider Actions & Billing Guidance

Prior Authorization

Prior Authorization (none specified)

No prior authorization statements are specified in this policy. Providers should be aware that an unlisted breast procedure (CPT 19499) is shown as an example code in the policy; inclusion of this code is for reference only and does not indicate coverage or prior authorization requirements.

Example unlisted procedure code: CPT 19499

Prior Authorization

Prior Authorization May Depend on Plan

UnitedHealthcare may use third-party tools (for example, InterQual®) to assist in administering benefits. Prior authorization requirements and routing may vary by plan, state, or contract; check the member's specific benefit plan for any plan-specific prior authorization procedures.

Prior authorization may depend on plan or contract
Check plan-specific prior authorization tools and routing

Background

Cytologic examination of epithelial cells obtained from breast ductal fluids — collected via techniques such as ductal lavage, nipple aspiration/aspirate fluid (NAF), or fiberoptic ductoscopy — has been studied as a potential early detection approach. However, studies report low sensitivity, substantial rates of inadequate or inconclusive samples, and technical limitations in sampling the full ductal system. These factors, together with the lack of evidence for improved clinical outcomes, limit the utility of ductal fluid cytology for routine screening or diagnosis.

Definitions

Ductal lavage (DL) — definition of invasive procedure

TermDuctal lavage (DL)

DefinitionAn invasive procedure that removes ductal fluid by inserting a microcatheter into the breast ducts via the nipple to collect epithelial cells for cytologic analysis.

Use contextStudied as a method to obtain ductal epithelial cells for cytologic examination as a potential early indicator of breast cancer.

Nipple aspirate fluid (NAF) — definition

TermNipple aspirate fluid (NAF)

DefinitionFluid obtained noninvasively or with fine-needle aspiration from the nipple used for cytologic, proteomic, or molecular analysis.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination of Breast Fluids for Cancer Screening or Diagnosis (for Louisiana Only)

Policy CodePolicy CS029LA.R

Change TypeRetirement / Revision (effective 11/01/2025retired 04/01/2026)

Effective DateNovember 1, 2025 - March 31, 2026

Next Review DateN/A

SourceLink

On This Page

Step Therapy

Step Therapy (not specified)

No step therapy requirements are specified in this policy. Services identified in this document as unproven or not medically necessary are not subject to step-therapy sequencing within this policy.

No step therapy requirements listed
Unproven/not medically necessary services are not supported by step therapy in this policy

Note

Provider Actions (placeholder)

This placeholder callout is included so writers can handle any provider-action text found elsewhere in the source. If specific provider actions (e.g., documentation tasks, routing instructions) are identified, replace this block with the actionable guidance; otherwise retain as a full-document reminder to follow plan terms.

Default: follow the full policy and plan terms for provider actions

Billing Rule

Coding and Benefit Note

The listed procedure and diagnosis codes are provided for reference only and do not guarantee coverage or payment. Inclusion does not imply a right to reimbursement. Always verify coding and billing guidance with the member's benefit plan and applicable payer billing rules.

Codes listed in this policy are for reference only
Inclusion of a code does not imply coverage or reimbursement rights

Note

Plan Benefit Verification

Before making coverage determinations, verify federal, state, and contractual benefit plan coverage terms. These requirements may differ from UnitedHealthcare standard benefit plans and, in case of conflict, govern coverage decisions.

Check federal, state, and contractual benefit terms which may override standard policy

Denial Risk

Not Medically Necessary Services

The following are considered unproven and not medically necessary for breast cancer screening, diagnosis, or as alternatives to guide surgery: ductal lavage; breast ductal fluid aspiration and cytology; and fiberoptic ductoscopy (with or without ductal lavage). Services meeting these descriptions are not supported by sufficient evidence of efficacy.

Breast ductal lavage — considered unproven/not medically necessary
Breast ductal fluid aspiration and cytology — considered unproven/not medically necessary
Fiberoptic ductoscopy (with or without ductal lavage) — considered unproven/not medically necessary

Note

Benefit Terms Govern Coverage

Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws. In the event of a conflict between this policy and those requirements, the federal, state, or contractual requirements govern.

Federal, state, or contractual benefit requirements govern coverage in case of conflict with this policy

Evidence contextStudies report limited diagnostic sensitivity but have evaluated hormone concentrations and cytologic concordance with ductoscopy; evidence for clinical benefit is limited.

Fiberoptic ductoscopy — definition

TermFiberoptic ductoscopy

DefinitionUse of a very thin endoscope to directly visualize breast ducts and obtain ductal fluid, often performed with aspiration cytology or biopsy.

Technical noteAllows direct evaluation of abnormal nipple discharge in conjunction with aspiration cytology, biopsy, or surgical excision.

Fiberoptic ductoscopy (FDS) — invasive endoscopic technique

TermFiberoptic ductoscopy (FDS)

DefinitionAn invasive endoscopic technique for intraductal visualization of the breast ducts used to evaluate pathological nipple discharge and locate intraductal lesions; has technical challenges and limited ductal reach.

Evidence/limitationsMost evidence is limited to preliminary cross-sectional studies; procedure is technically challenging, examines only a small portion of the ductal system, and lacks high-quality data showing improved detection rates or mortality benefits.

Nipple aspirate fluid (NAF) — evidence context

TermNipple aspirate fluid (NAF)

DefinitionFluid collected from the nipple used for cytologic and biochemical analysis to assess breast pathology and potential biomarkers.

Evidence summaryResearch includes hormone concentration analyses and paired cytology comparisons with ductoscopy; sensitivity is generally low and evidence is insufficient to demonstrate clinical outcome benefit.